Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 7Terminated 5Unknown 4Active not recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Stomach Neoplasms 1Recurrence 1Pseudomyxoma Peritonei 1Neoplasms, Plasma Cell 1Carcinoma, Ovarian Epithelial 1Atrophy 1Appendiceal Neoplasms 1

Interventions

Dexamethasone 116Lenalidomide 75daratumumab 58Bortezomib 53carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 27isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12Melphalan 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × Clarithromycin × Clear all
NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
11 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01559935 2025-09-08

CarBiRD

Weill Medical College of Cornell University

Phase 2 Active not recruiting
74 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡